ReviewNature reviews. Clinical oncology2012
Latest advances and current challenges in the treatment of multiple myeloma.
Review in Nature reviews. Clinical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 202 citations in OpenAlex.
- Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy.International journal of clinical and experimental pathology · 2015Trial
- GP130 activation induces myeloma and collaborates with MYC.The Journal of clinical investigation · 2014Trial
- A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.Cancer medicine · 2014Trial
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.Blood · 2014Trial
- Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma.BioMed research international · 2014Trial
- Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma.Theranostics · 2026Article
- Hypoglycemic Agents Increase Regulatory Factor X1 to Inhibit Cancer Cell Behaviour in Human Glioblastoma Cells.Journal of cellular and molecular medicine · 2024Article
- Pro-survival signaling regulates lipophagy essential for multiple myeloma resistance to stress-induced death.Cell reports · 2024Article
- The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway.Journal of translational medicine · 2023Article
- Article
- A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma.Drug delivery and translational research · 2023Article
- Icaritin-elevated circ_0000190 suppresses the malignant progression of multiple myeloma by targeting miR-301a.The Kaohsiung journal of medical sciences · 2022Article
- Blocking the PCNA/NKp44 Checkpoint to Stimulate NK Cell Responses to Multiple Myeloma.International journal of molecular sciences · 2022Article
- Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Article
- The designed NF-κB inhibitor, DHMEQ, inhibits KISS1R-mediated invasion and increases drug-sensitivity in mouse plasmacytoma SP2/0 cells.Experimental and therapeutic medicine · 2021Article
- Review
- [Transcription factor EB related autophagy in the treatment of multiple myeloma and its mechanism].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- RFX1: a promising therapeutic arsenal against cancer.Cancer cell international · 2021Review
- Article
- Tracking myeloma tumor DNA in peripheral blood.Best practice & research. Clinical haematology · 2020Review
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effectively treating patients with multiple myeloma is challenging. The development of therapeutic regimens over the past decade that incorporate the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide has been the cornerstone of improving the outcome of patients with myeloma. Although these treatment regimens have improved patient survival, nearly all patients eventually relapse. Our improved understanding of the biology of the disease and the importance of the microenvironment has translated into ongoing work to help overcome the challenge of relapse. Several classes of agents including next-generation proteasome inhibitors, immunomodulatory agents, selective histone-deacetylase inhibitors, antibody and antitumor immunotherapy approaches are currently undergoing preclinical and clinical evaluation. This Review provides an update on the latest advances in the treatment of multiple myeloma. In particular, we focus on novel therapies including modulating protein homeostasis, kinases inhibitors, targeting accessory cells and cytokines, and immunomodulatory agents. A discussion of the challenges associated with these therapeutic approaches is also presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.